Research Article
Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer
Table 4
Univariate analysis and multivariate analysis of overall survival time.
| Variable category | Category | HR (95% CI) | value | HR (95% CI) | value |
| Gender | Female versus male | 0.99 (0.64-1.52) | 0.955 | 0.82 (0.48-1.39) | 0.468 | Age | ⩾59 versus <59 | 1.29 (0.87-1.89) | 0.199 | 1.34 (0.83-2.18) | 0.230 | ECOG | ⩾2 versus 0-1 | 1.18 (0.67-2.08) | 0.557 | 1.58 (0.85-2.93) | 0.146 | Tumor_location | Cardia versus body/fundus versus pylorus | 0.89 (0.70-1.12) | 0.103 | 0.99 (0.74-1.33) | 0.968 | Histological_differentiation | Poorly versus moderately and well | 1.92 (1.29-2.86) | 0.001 | 1.89 (1.21-2.94) | 0.005 | No. of metastasis organs | ≥2 versus <2 | 1.39 (0.87-2.20) | 0.156 | 1.15 (0.71-1.87) | 0.564 | Liver metastasis | Yes versus no | 0.84 (0.57-1.25) | 0.396 | 0.88 (0.54-1.41) | 0.584 | Smoking_history | Smoke versus never smoked | 1.40 (0.96-2.06) | 0.077 | 1.38 (0.78-2.43) | 0.271 | Drinking_history | Drink versus never drinked | 0.73 (0.49-1.07) | 0.110 | 0.73 (0.42-1.26) | 0.259 | Anti-PD-1 therapy line | First line versus second line and third line | 0.551 (0.38-0.80) | 0.002 | 0.64 (0.39-1.06) | 0.086 | Treatment type | Anti-PD-1 plus chemotherapy versus anti-PD-1 monotherapy or antiangiogenesis | 0.49 (0.33-0.73) | <0.001 | 0.73 (0.43-1.24) | 0.249 | Baseline NLR | <3.23 versus ≥3.23 | 0.38 (0.26-0.57) | <0.001 | 0.34 (0.22-0.52) | <0.001 |
|
|
CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio.
|